Azitra (AZTR) Share-based Compensation (2022 - 2026)
Azitra (AZTR) posted Share-based Compensation of $6149.0 for Q1 2026, down 49.37% on a QoQ basis from $12146.0 in Q4 2025, and down 79.77% year-over-year from $30402.0 in Q1 2025.
Azitra (AZTR) Share-based Compensation (2022 - 2026) Analysis & Trends
Azitra's Share-based Compensation history runs 5 years deep, the most recent figure standing at $6149.0 for Q1 2026.
- Quarterly Share-based Compensation fell 79.77% year-over-year to $6149.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38491.0 (down 84.05% YoY) and the FY2025 annual result came in at $62744.0, down 74.4% from the prior year.
- Share-based Compensation was $6149.0 for Q1 2026 at Azitra, down from $12146.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $143534.0 in Q3 2024 and bottomed at $4165.0 in Q3 2025.
- A 5-year average of $37058.3 and a median of $34170.5 in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation surged 267.35% — and 2025, when it sank 97.1%.
- Azitra's Share-based Compensation stood at $29327.0 in 2022, then advanced by 18.81% to $34844.0 in 2023, then retreated by 4.78% to $33178.0 in 2024, then tumbled by 63.39% to $12146.0 in 2025, then plunged by 49.37% to $6149.0 in 2026.
- Business Quant data shows AZTR's Share-based Compensation at $6149.0 in Q1 2026, $12146.0 in Q4 2025, and $4165.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,769.80 Bn | 1,769.74 Bn | - | - |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | 305,000.00 |
| 3 | BeOne Medicines | 473.64 Bn | 468.85 Bn | 1.35 Bn | 9.26 Mn |
| 4 | Vertex Pharmaceuticals | 123.74 Bn | 116.49 Bn | 2.59 Bn | 166.40 Mn |
| 5 | Regeneron Pharmaceuticals | 71.73 Bn | 62.97 Bn | 3.31 Bn | 257.40 Mn |
| 6 | Belite Bio | 62.10 Bn | 62.10 Bn | - | - |
| 7 | Argenx Se | 54.68 Bn | 49.49 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 38.13 Bn | 35.12 Bn | 959.66 Mn | - |
| 9 | Revolution Medicines | 36.21 Bn | 36.21 Bn | - | 87.30 Mn |
| 10 | Azitra | 2.03 Mn | 2.03 Mn | - | 6,149.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6,149.00 |
| Mar 31, 2026 | 6,149.00 |
| Dec 31, 2025 | 12,146.00 |
| Dec 31, 2025 | 12,146.00 |
| Sep 30, 2025 | 4,165.00 |
| Sep 30, 2025 | 4,165.00 |
| Jun 30, 2025 | 16,031.00 |
| Jun 30, 2025 | 16,031.00 |
| Mar 31, 2025 | 30,402.00 |
| Mar 31, 2025 | 30,402.00 |
| Dec 31, 2024 | 33,178.00 |
| Dec 31, 2024 | 33,178.00 |
| Sep 30, 2024 | 143,534.00 |
| Sep 30, 2024 | 143,534.00 |
| Jun 30, 2024 | 34,170.00 |
| Jun 30, 2024 | 34,170.00 |
| Mar 31, 2024 | 34,171.00 |
| Mar 31, 2024 | 34,171.00 |
| Dec 31, 2023 | 34,844.00 |
| Dec 31, 2023 | 34,844.00 |